Donald A Berry PhDProfessor, Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Donald Berry is professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. He received his Ph.D. in statistics from Yale University and has served on the faculty the University of Minnesota and Duke University. He has held endowed positions at Duke and M.D. Anderson. He has authored many books on biostatistics and over 400 peer-reviewed articles. He is a Thomson Reuters Highly Cited Researcher in recognition of ranking among the top 1% of most cited researchers in Clinical Medicine. He has received numerous research grants from the NIH and NSF and is Fellow of the American Statistical Association, the Institute of Mathematical Statistics, and the International Society of Bayesian Analysis. He has designed many innovative clinical trials in cancer and in virtually every other therapeutic area, including adaptive Bayesian trials. He is founder and co-owner of Berry Consultants, a company that has designed and helped run innovative trials for pharmaceutical companies, medical device companies, patient advocacy groups, and for international consortia in Alzheimer’s disease, cancer, Ebola, sepsis, community-acquired pneumonia and other diseases.
Donald Berry is founder and co-owner of Berry Consultants LLC, a company that designs and helps run Bayesian adaptive clinical trials for pharmaceutical companies, medical device companies, patient advocacy groups, and international consortia. Genentech/F.Hoffmann-La Roche, Ltd. is a client of Berry Consultants.